The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 07, 2020

Filed:

Apr. 12, 2016
Applicant:

Cell Signaling Technology, Inc., Danvers, MA (US);

Inventors:

Ting-Lei Gu, Woburn, MA (US);

Ailan Guo, Lexington, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/53 (2006.01); C12Q 1/6886 (2018.01); C12Q 1/6813 (2018.01); C12Q 1/6883 (2018.01); C07K 14/74 (2006.01); C07K 14/82 (2006.01); C07K 16/40 (2006.01); C12N 9/99 (2006.01); C12N 15/113 (2010.01); C12N 9/12 (2006.01); C12Q 1/68 (2018.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C07K 14/70539 (2013.01); C07K 14/82 (2013.01); C07K 16/40 (2013.01); C12N 9/12 (2013.01); C12N 9/99 (2013.01); C12N 15/1137 (2013.01); C12Q 1/6813 (2013.01); C12Q 1/6883 (2013.01); G01N 33/53 (2013.01); A61K 2039/505 (2013.01); C07K 2319/00 (2013.01); C12Q 1/68 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Y 207/10001 (2013.01);
Abstract

In accordance with the invention, a novel gene translocation, (5q32, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of CD74 with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The CD74-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of the new fusion protein enables new methods for determining the presence of these mutant ROS kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.


Find Patent Forward Citations

Loading…